Three-year changes in renal function after switching from injectable GLP-1 receptor agonists to oral semaglutide in Japanese patients with type 2 diabetes: a retrospective cohort study.

Takashima S, Terui K, Yamada F, Shimotomai T

Diabetology international30 Apr 2026

PMID42078492DOI10.1007/s13340-026-00903-8PepBankPUB-42078492

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with T2D, switching to oral semaglutide was linked to lower UACR after three years than before switching.
In plain wordsIn patients with diabetes, switching to oral semaglutide was linked to less urine albumin than before switching.
Peptide
Semaglutide
Outcome
DecreaseUrinary albumin-to-creatinine ratio
Study
n = 36
Comparator
Before switch from liraglutide or dulaglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
7 mg/day · oral · 3 yearsAs given in this study (human).
Measurements
Median UACR
54.3 mg/g creatinine
before switch
Median UACR
35.8 mg/g creatinine
after switch
Source sentences
Summary
Three years after switching, the median UACR significantly decreased from 54.3 to 35.8 mg/g creatinine (p < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
Report a problemFND-4207849201
02HumanObservational studyEfficacy outcome
In patients with T2D, switching to oral semaglutide was linked to improved annual eGFR slope compared with before switching.
In plain wordsIn patients with diabetes, switching to oral semaglutide was linked to slower kidney decline than before switching.
Peptide
Semaglutide
Outcome
IncreaseAnnual eGFR slope
Study
n = 36
Comparator
Before switch from liraglutide or dulaglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
7 mg/day · oral · 3 yearsAs given in this study (human).
Measurements
eGFR slope
−1.92 mL/min/1.73 m²/year
before switch
eGFR slope
−0.26 mL/min/1.73 m²/year
after switch
eGFR slope difference
1.67 mL/min/1.73 m²/year
after versus before switch
Source sentences
Summary
The annual eGFR slope improved from - 1.92 (95% CI - 2.66 to - 1.18) before switching to - 0.26 (95% CI - 1.01 to 0.50) mL/min/1.73 m²/year after switching (difference: 1.67; p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
Report a problemFND-4207849202
03HumanObservational studyEfficacy outcome
In patients with T2D, switching to oral semaglutide was linked to sustained glycated hemoglobin reduction at three years versus baseline.
In plain wordsIn patients with diabetes, glycated hemoglobin remained lower than baseline after switching to oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseGlycated hemoglobin
Study
n = 36
Comparator
Before switch from liraglutide or dulaglutide
Outcome group
Glycemic control · Metabolic and weight
Studied dose
7 mg/day · oral · 3 yearsAs given in this study (human).
Measurements
Glycated hemoglobin change
−0.33%
three years after switch
Source sentences
Summary
Reductions in glycated hemoglobin (- 0.33%, p p < 0.01) were sustained at 3 years.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
Report a problemFND-4207849204
04HumanObservational studyEfficacy outcome
In patients with T2D, switching to oral semaglutide was linked to sustained weight reduction at three years versus baseline.
In plain wordsIn patients with diabetes, weight remained lower than baseline after switching to oral semaglutide.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n = 36
Comparator
Before switch from liraglutide or dulaglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
7 mg/day · oral · 3 yearsAs given in this study (human).
Measurements
Body weight change
−3.5 kg
three years after switch
Source sentences
Summary
Reductions in glycated hemoglobin (- 0.33%, p p < 0.01) were sustained at 3 years.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
Report a problemFND-4207849205
05HumanObservational studyEfficacy outcome
In patients with baseline eGFR at least 60, switching to oral semaglutide was linked to improved eGFR slope compared with before switching.
In plain wordsIn patients with higher initial kidney function, switching to oral semaglutide was linked to slower kidney decline than before switching.
Peptide
Semaglutide
Outcome
IncreaseAnnual eGFR slope with preserved baseline eGFR
Study
n: not reported in source
Comparator
Before switch from liraglutide or dulaglutide
Outcome group
Kidney function · Kidney and urinary
Studied dose
7 mg/day · oral · 3 yearsAs given in this study (human).
Measurements
eGFR slope difference
1.85 mL/min/1.73 m²/year
baseline eGFR ≥60
Source sentences
Summary
Subgroup analysis showed a significant improvement in eGFR slope among patients with baseline eGFR ≥ 60 mL/min/1.73 m² (difference: 1.85; p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
Report a problemFND-4207849203

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

06HumanNot a test of Semaglutide aloneObservational studyOther
In patients with T2D after switching to oral semaglutide, eGFR slope improvement was linked to the magnitude of weight loss.
In plain wordsIn patients with diabetes after switching to oral semaglutide, slower kidney decline was linked to the amount of weight loss.
Peptide
Semaglutide
Outcome
Not applicableeGFR slope association with weight loss
Study
n = 36
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Improvement in eGFR slope was significantly associated with the magnitude of weight loss (p p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4207849206
07HumanNot a test of Semaglutide aloneObservational studyOther
In patients with T2D after switching to oral semaglutide, eGFR slope improvement was linked to lower baseline HbA1c.
In plain wordsIn patients with diabetes after switching to oral semaglutide, slower kidney decline was linked to lower initial HbA1c.
Peptide
Semaglutide
Outcome
Not applicableeGFR slope association with baseline HbA1c
Study
n = 36
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Improvement in eGFR slope was significantly associated with the magnitude of weight loss (p p < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective cohort study included 36 patients with type 2 diabetes (T2D) who were switched from liraglutide or dulaglutide to oral semaglutide (7 mg/day).
Summary · context
Changes in the urinary albumin-to-creatinine ratio (UACR) and annual estimated glomerular filtration rate (eGFR) slope were compared between the 3-year periods immediately before and after the switch.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4207849207

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
22 Oct 2026, 02:25 UTC
Study results updated
Versions 2 to 3
21 Oct 2026, 18:59 UTC
The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.